IXALTIS is a pharmaceutical company specialized in the development of therapeutic treatments in the field of urology.
The company was created thanks to the expertise of leading medical specialists and experienced managers.
Ixaltis has a worldwide license to develop in a new indication 3 molecules from Sanofi.
Investor(s):
Hasnaa Hafid
Hasnaa Hafid
Participation: minoritaire
Activities:
Pharmaceutical research and development (urinary incontinence)
Leaders:
Roberto GRADNIK
IXO intervention: 2,53 M€
Sales figures: nc
Effective: nc